Hematologic cancer develops in some patients receiving lentiviral elivaldogene autotemcel (eli-cel) gene therapy for cerebral ...

Viking Therapeutics has announced positive results from its Phase Ib clinical trial of VK0214, a thyroid hormone receptor ...

Most boys treated with breakthrough gene therapy for a rare but deadly brain illness are faring well six years later, ...

Seven out of 67 children who were given bluebird's (BLUE) gene therapy Skysona during clinical trials ended up developing ...

Researchers report that 94% of patients treated with the gene therapy eli-cel for cerebral adrenoleukodystrophy (CALD) have ...

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for ...

Pfizer shared that the combination of its drugs Talzenna and Xtandi extended survival in men with metastatic ...

Seven young boys given Bluebird's Skysona later developed blood cancers, findings that could shape how doctors balance the gene therapy’s risks against its benefit.

Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), retaining the price target of ...

Viking Therapeutics (VKTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

The technology is part of a broader industry shift towards precision medicine, says GlobalData analyst Cynthia Stinchcombe.